BiochemistrybioRxivPreprint
Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEF
Saswata S. Sarkar, Meredith A. Redd, James J. Hartman…·Fady I. Malik
This paper describes ulacamten, a novel cardiac myosin inhibitor with distinct binding and inhibitory properties compared to existing CMIs, showing efficacy in improving cardiac function in a rodent model of HFpEF.